e.g. mhealth
Search Results (1 to 10 of 29 Results)
Download search results: CSV END BibTex RIS
CSV download: Download all 29 search results
(up to 5,000 articles maximum)
- 9 JMIR Cancer
- 5 Journal of Medical Internet Research
- 4 JMIR Formative Research
- 4 JMIR Research Protocols
- 3 JMIR Dermatology
- 3 JMIRx Med
- 1 JMIR Public Health and Surveillance
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Moreover, patients treated with ICIs may live longer, thereby increasing their window of risk for developing SPCs, which could paradoxically elevate SPC incidence in this group despite a protective effect of immunotherapy.
Our findings align with prior studies suggesting a decreased incidence of patients with SPCs treated with ICIs, such as those by Heudel et al [4-7].
JMIR Cancer 2025;11:e64900
Download Citation: END BibTex RIS
One of the pivotal treatment modalities in the field of CRC is immunotherapy, especially the administration of immune checkpoint inhibitors (ICIs), including antiprogrammed cell death-1 (PD-1) and antiprogrammed cell death ligand 1 (PD-L1) antibodies [4]. A reliable predictor of immunotherapy response and immunoactivity is MSI-H status; notably, the Food and Drug Administration and the European Medicines Agency granted approval for the use of ICIs to treat MSI-H CRC in 2017 and 2021, respectively [5-7].
JMIR Form Res 2025;9:e66960
Download Citation: END BibTex RIS
This multicenter, randomized, phase 2 trial across 15 centers in 6 European countries investigated the efficacy of combining stereotactic radiotherapy and immunotherapy in prolonging progression-free survival while minimizing toxicity and preserving quality of life for patients with non–small cell lung cancer (NSCLC).
J Med Internet Res 2025;27:e71817
Download Citation: END BibTex RIS
Recent advancements in immunotherapy, notably the application of programmed cell death protein-1 (PD-1) inhibitors, have markedly improved patient prognosis. These agents not only effectively suppress tumor progression but also enable surgical intervention in selected cases of late-stage disease.
JMIR Cancer 2025;11:e67379
Download Citation: END BibTex RIS
Besides, immunotherapy-related adverse events (ir AEs) have been observed with the increasing frequency and duration of immunotherapy usage. Patients’ decisions to undergo immunotherapy are influenced by a range of factors, including their perceptions of its efficacy, side effects, procedural aspects, costs, their levels of knowledge about the treatment, and the comprehensiveness of advice provided by health care providers [5,6].
J Med Internet Res 2025;27:e60948
Download Citation: END BibTex RIS
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapies with BRAF/MEK inhibitors have significantly improved clinical outcomes for patients with melanoma and have become standard treatment for patients with high-risk and advanced disease [1-6]. Nevertheless, these novel systemic treatments are associated with short- and long-term (immune-related) adverse events (AEs) [7-10].
JMIR Cancer 2025;11:e58938
Download Citation: END BibTex RIS
We aimed to recruit three participant groups; individuals diagnosed with melanoma previously treated with immunotherapy, those with renal cell carcinoma previously treated with immunotherapy, and participants without direct experience with the targeted cancer types nor with immunotherapy (thus patients with other types of cancer or informal caregivers). For each participant group, our goal was to recruit seven to nine participants.
JMIR Form Res 2025;9:e57659
Download Citation: END BibTex RIS
Nevertheless, a substantial proportion of patients fail to benefit from immunotherapy, particularly those with lung cancer liver metastases [5]. The existence of baseline liver metastases in patients with lung cancer has been connected with a reduced response to immunotherapy.
JMIR Res Protoc 2024;13:e59152
Download Citation: END BibTex RIS
For advanced NSCLC without driver gene mutations, immunotherapy—specifically inhibitors targeting programmed death receptor 1 (PD-1) and its ligand (PD-L1)—has significantly improved patient outcomes. The 5-year overall survival rate has reached 20%, and even 40% in patients with high PD-L1 expression [9]. As a result, immunotherapy is recommended by the NCCN [2] as a standard first-line treatment for this type of lung cancer and has become a mainstream treatment option in clinical practice.
JMIR Res Protoc 2024;13:e64950
Download Citation: END BibTex RIS
Immune checkpoint blockers (ICBs) are immunotherapy drugs that enhance the immune system’s ability to target cancer by inhibiting specific pathways that regulate immune cell activity, such as programmed cell death protein 1, programmed death ligand 1, and cytotoxic T-lymphocyte–associated protein 4 [5]. These pathways are often exploited by cancer cells to evade immune detection.
JMIR Cancer 2024;10:e53443
Download Citation: END BibTex RIS